Jaguar Health

209 articles about Jaguar Health

• REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., Jaguar’s New Italian Subsidiary

  4/21/2021

  Jaguar Health, Inc. issued a reminder about the Innovators with Jane King interview of Lisa Conte, the Company's founder, president, and CEO, and Josh Mailman, the lead sponsor of the Dragon special purpose acquisition company, that will air during a webcast this Friday, April 23, 2021, at 8:30 AM Eastern to provide a business overview of Napo EU S.p.A., Jaguar's wholly owned Italian subsidiary.

• Jaguar Health Announces Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., the Company's New Italian Subsidiary

  4/19/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) announced today that an Innovators with Jane King interview of Lisa Conte, the Company founder, president, and CEO, will be aired during a webcast this Friday, April 23, 2021, at 8:30 AM Eastern

• Jaguar Health Announces Upsizing of At-the-Market (ATM) Financing Program by $15.3 Million with Ladenburg Thalmann & Co. Inc. for Potential Future Financing Needs

  4/15/2021

  Merger of Napo EU and Dragon SPAC targeted for mid-2021 Jaguar kicks off educational awareness contest in honor of HIV Long-Term Survivors Awareness Day and the 40th anniversary of the first publication defining HIV

• Jaguar Health and Napo Pharmaceuticals Announce Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Annual Meeting

  4/14/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an abstract associated with cancer therapy-related diarrhea by Napo Pharmaceuticals, Inc.

• Jaguar Health Announces Amendment to March 2020 Equity Purchase Agreement with Oasis Capital, LLC

  4/8/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar has entered into an amendment to the March 24, 2020 equity purchase agreement Equity Purchase Agreement with Oasis Capital, LLC

• Jaguar Health Promotes Carol Lizak to Chief Financial Officer

  4/6/2021

  Jaguar Health, Inc. ) announced today that the Company has promoted Carol Lizak, an accomplished financial executive, to the expanded role of chief financial officer.

• Jaguar Health Reports 2020 Financial Results and Business Updates

  3/31/2021

  Jaguar Health, Inc. reported consolidated financial results for the year ended December 31, 2020.

• Jaguar Health Announces Selection of Investment Bank and Nominated Advisor for Proposed Merger of the Dragon SPAC and Napo EU, Jaguar's Italian Subsidiary

  3/30/2021

  Update regarding March 15, 2021 meeting with European regulatory authority regarding potential Covid-related indication for crofelemer

• Jaguar Health Announces Winner of International Day of Forests Contest

  3/22/2021

  New educational contest to begin in April in honor of HIV Long-Term Survivors Awareness Day and the 40th anniversary of the first publication defining HIV

• Jaguar Health Announces Incorporation of Napo EU Subsidiary in Italy

  3/15/2021

  Napo EU will serve as the foundation of the Companys efforts to address the growing burden - particularly in Europe - of the inflammatory diarrhea associated with long-hauler syndrome in the post COVID-19 patient population In honor of International Day of Forests, Company is conducting a survey contest to raffle off a signed print of an original painting of a Jaguar by Anthony J. Conte - link to entry form appears below

• Jaguar Health Signs Definitive Agreement for $5 Million Non-dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream

  3/9/2021

  No royalty payments due for 36 months Company has started to identify key opinion leader physicians in the US as well as Europe focused on addressing the symptoms - including gastrointestinal distress - that afflict a significant proportion of COVID-19 survivors for an extended period after recovery SAN FRANCISCO, CA / ACCESSWIRE / March 9, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has signed the definitive

• Jaguar Health Enters Binding Term Sheet for $5 Million Non-dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream

  3/5/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has entered a binding agreement of terms (the "Term Sheet") for a third non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the lender for an aggregate purchase price of $5 million

• Jaguar Health Launches Website for Napo EU

  2/23/2021

  Site contains links to information about post-COVID-19 long-hauler syndrome An article published yesterday in the San Francisco Chronicle references diarrhea as long-hauler symptom and the theory that the type of inflammation associated with HIV may also be present in long-hauler patients Napo EU to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in long-hauler COVID-19 recovery patients in Europe SAN F

• Jaguar Health Announces Commitment to Move Forward with Exclusive Relationship with the Planned Dragon SPAC, which is Pursuing Listing on AIM Italia and Plans to Target Napo EU

  2/19/2021

  Napo EU continues to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler' covid-19 recovery patients in Europe

• Jaguar Health Signs Memorandum of Understanding with the Lead Sponsor of the Planned Dragon SPAC Pursuing Listing on AIM Italia, Providing the Dragon SPAC with Exclusivity for a Proposed Business Combination with Napo EU

  2/18/2021

  Napo EU to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler' covid-19 recovery patients in Europe

• Noted Natural Products Industry Veteran Dr. Nigel Gericke Joins Scientific Strategy Team for Jaguar Health’s Recently Launched Mental Health Entheogen Therapeutics Initiative

  2/9/2021

  Jaguar Health announced today that noted natural products industry veteran Dr. Nigel Gericke has joined the scientific strategy team (SST) for the company's recently launched mental health Entheogen Therapeutics Initiative

• Jaguar Health's Chief of Sustainable Supply, Dr. Steven King, an Ethnobotanist, to Discuss Crofelemer Development on February 4th at 2 PM Eastern

  2/3/2021

  Webinar Title: The Development of Crofelemer: Connecting Ethnobotany, Conservation, Biocultural Diversity, Indigenous Knowledge and Global Public Health

• REMINDER: Jaguar Health and Sponsor of Proposed Post Pandemic Recovery Equity SPAC to Host Webcast Wednesday, January 27th at 8:30 AM Eastern Time

  1/26/2021

  Webcast registration link appears below Andreea Porcelli, CEO of Swiss Growth Forum, will be a co-presenter on the webcast in her separate capacity as a sponsor of the proposed SPAC Andreea Porcelli and Jaguar CEO Lisa Conte interviewed again on Innovators with Jane King

• Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  1/22/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) announced today that effective December 9, 2020, the Company granted nonstatutory stock options for the purchase of up to 1,500 shares of the Companys common stock to one new employee, and nonstatutory stock options for the purchase of up to 35,000 shares of the Companys common stock

• Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement

  1/22/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on January 21, 2021 the Company received formal notice that Jaguar has regained compliance with the bid price requirement, as required by the decision of the Nasdaq Hearings Panel (the "Panel") dated October 28, 2020 (the "Decision").